Home / Business and Economy / Rossari Biotech Q3: Profit Up, Margins Dip
Rossari Biotech Q3: Profit Up, Margins Dip
17 Jan
Summary
- Net profit increased by 3.2% to ₹32.7 crore.
- Revenue saw a 13.4% jump to ₹581.6 crore.
- Company margins contracted to 11.8% from 12.6%.
Mumbai-based specialty chemical firm Rossari Biotech Ltd. announced its financial results for the third quarter on Saturday, January 17, 2026. The company reported an increase in its net profit, revenue, and EBITDA compared to the same period last year. Despite these gains, Rossari Biotech's profit margins experienced a contraction.
The company's net profit saw a 3.2% rise, reaching ₹32.7 crore, up from ₹31.7 crore in the prior year's third quarter. Concurrently, revenue grew by 13.4% to ₹581.6 crore, compared to ₹512.7 crore in the previous fiscal's third quarter. Earnings before interest, tax, depreciation, and amortization (EBITDA) also climbed by 6.3% year-on-year to ₹68.8 crore.
However, a key concern was the contraction in the company's margins, which decreased to 11.8% from 12.6% reported in the corresponding period of the previous year. In related market news, shares of Rossari Biotech closed nearly 1% lower in the previous trading session at ₹534.5 per share, reflecting a 33.6% decline over the past year.
